Herceptin eradicates tumours and may reduce the need for mastectomies in women with inflammatory HER2-positive breast cancer – one of the most aggressive and fastest growing forms of the disease.
The Food and Drug Administration is alerting health care professionals and consumers to concerns over the use of Fentora (fentanyl buccal) tablets after recent reports of deaths and other adverse events.
In clinical research, patients with advanced non-small cell lung cancer (NSCLC) that are classified as having a non-squamous histology achieve statistically significant higher survival when treated in the second-line setting with ALIMTA® (pemetrexed for injection) when compared to histologically-similar patients treated with docetaxel.
Women diagnosed with metastatic breast cancer who have also endured previous traumatic or stressful events see their cancer recur nearly twice as fast as other women, according to a report by a University of Rochester Medical Center scientist.
Researchers at the Centre for Addiction and Mental Health (CAMH) have clarified the link between alcohol consumption and the risk of head and neck cancers, showing that people who stop drinking can significantly reduce their cancer risk.
The part of the prostate that is biopsied may matter more than the number of biopsy samples taken for accurately diagnosing prostate cancer.
An alternative design for phase II cancer clinical trials may improve success rates for new cancer drugs in phase III trials.
New Phase II data presented today suggest that ZD4054, a novel compound in development for the treatment of men with Hormone Resistant Prostate Cancer (HRPC), could offer a promising improvement in overall survival in men with metastatic HRPC who were asymptomatic or mildly symptomatic for pain.1 Patients who received ZD4054 10mg once-daily experienced a 45 percent reduction in the risk of death compared to placebo (HR 0.55; 80 percent CI 0.41, 0.73).
A report from the American Cancer Society finds the breast cancer death rate in the United States continues to drop more than two percent per year, a trend that began in 1990 and is credited to progress in early detection and treatment.
A randomized controlled trial of two continuing medical education (CME) approaches aimed at improving communication between doctors and breast cancer patients finds varied effects.